Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Recruiting · NCT07180082 · Registry updated 2025-11-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer | Advanced Breast Cancer | Recruiting | Phase 2 | 2025-11-18 | NCT07180082 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Wenjin Yin | 8 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University | Shanghai | China | 18 |